Literature DB >> 14503951

Positron emission tomography in patients with Hodgkin's disease: correlation to histopathologic subtypes.

Natascha Döbert1, Christian Menzel, Uwe Berner, Nadja Hamscho, Nicola Wördehoff, Paris Mitrou, Frank Grünwald.   

Abstract

The aim of this study was to evaluate the initial staging and restaging of Hodgkin's disease (HD) according to histopathologic subtype (HST) using fluorine-18-deoxyglucose-positron emission tomography (PET). Special attention was paid to the accuracy of PET for detection of bone marrow infiltration (BMI). 44 patients with HD (m:f = 28:16, mean age 36 +/- 15 years) underwent PET; 16 were primary stagings and 28 restaging examinations. PET results were compared with methods of conventional staging including computed tomography (CT) and bone marrow biopsy. Viable tumor tissue was detected by PET in 25/44 cases, 16 nodular sclerosis (NS), 4 mixed cellularity (MC), 3 lymphocyte predominance (LP) and 2 cases with a nonclassified subtype (NC). FDG tumor uptake, measured as standard uptake value (SUV), ranged from 1.7 to 13. Maximum SUV in NS was 5.2 +/- 1.5 (2.5-7.3), 3.2 +/- 2.4 for MC, 2.6 +/- 0.7 for LP, and 9.1 +/- 3.8 for NC, respectively. In 7% of all patients (3/44) bone marrow infiltrations were detected by PET. PET is known for its superior detection of viable tissue in HD. In this study it was shown that HST does not influence the intensity of glucose metabolism, although 2 patients with NC showed the highest SUVs. In addition PET accurately detected focal BMI and may thus be applied before BMB to guide its optimal use.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14503951     DOI: 10.1089/108497803322287646

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  3 in total

1.  18F-FDG PET Imaging Features of Patients With Autoimmune Lymphoproliferative Syndrome.

Authors:  Jorge A Carrasquillo; Clara C Chen; Susan Price; Millie Whatley; Nilo A Avila; Stefania Pittaluga; Elaine S Jaffe; V Koneti Rao
Journal:  Clin Nucl Med       Date:  2019-12       Impact factor: 7.794

2.  Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients.

Authors:  Gang Cheng; Wengen Chen; Wichana Chamroonrat; Drew A Torigian; Hongming Zhuang; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-20       Impact factor: 9.236

3.  Performance of FDG PET/CT at initial diagnosis in a rare lymphoma: nodular lymphocyte-predominant Hodgkin lymphoma.

Authors:  Jean François Grellier; Laetitia Vercellino; Thierry Leblanc; Pascal Merlet; Catherine Thieblemont; Pierre Weinmann; Marie-Elisabeth Toubert; Nathalie Berenger; Josette Brière; Pauline Brice
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-06-26       Impact factor: 9.236

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.